Phase 3
Completed N=100
TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
Attention Deficit Disorder With Hyperactivity
Source: ClinicalTrials.gov NCT02083783 ↗
Enrolled (actual)
100
Serious AEs
0.0%
Results posted
Aug 2020
Primary outcomePrimary: SKAMP (Swanson, Kotkin, Agler, M-Flynn, and Pelham Scale) — -9.1; 5.6 score on a scale — p=<0.0001
◆ Published Evidence
Emerging
5citations · ~2 / year
Efficacy of Amphetamine Extended-Release Oral Suspension in Children with Attention-Deficit/Hyperactivity Disorder: Effect Size Across the Day.
Summary
The purpose of this study is to determine whether TRI102 is effective in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children ages 6-12.
Linked Publications
-
Efficacy of Amphetamine Extended-Release Oral Suspension in Children with Attention-Deficit/Hyperactivity Disorder: Effect Size Across the Day.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY SKAMP (Swanson, Kotkin, Agler, M-Flynn, and Pelham Scale) |
-9.1; 5.6 | <0.0001 sig |
| SECONDARY PERMP (Permanent Product Measure of Performance). |
25.3; -13.6 | <0.0001 sig |
Eligibility Criteria
Inclusion Criteria
- Children aged 6 to 12 years with ADHD who require pharmacologic treatment for this condition
Exclusion Criteria
- Other serious illnesses or conditions that would put the patient at particular risk for safety events or would interfere with treatment/assessment of ADHD
Data sourced from ClinicalTrials.gov (NCT02083783) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.